nSMase3: Novel neutral Sphingomyelinase and its use for diagnostics andtherapy with focus on heart muscle diseases and male fert

A novel human TNF-responsible neutral phingomyelinase enzyme (nSMase3) has been identified. Furthermore, the invention relates to the use of nSMase3 as pharmaceutical and diagnostic target

and to appropriate test systems. The human enzyme was identified by screening database sequences with up to now unknow n function w ith a short sequence derived from a bovine neutral sphingomyelinase. The identified nSMase3 shows no significant homologies to the well-know n human neutral sphingomyelinases type 1 and type 2.

Further Information: PDF

PROvendis GmbH
Phone: +49 (0)208/94105 0

Contact
Dipl.-Ing. Alfred Schillert

Media Contact

info@technologieallianz.de TechnologieAllianz e.V.

All latest news from the category: Technology Offerings

Back to home

Comments (0)

Write a comment

Newest articles

New anti-cancer agent works without oxygen

Why tumors shrink but don’t disappear. “As tumors grow very quickly, consume a lot of oxygen and their vascular growth can’t necessarily keep pace, they often contain areas that are…

First blueprint of the human spliceosome revealed

Researchers detail the inner workings of the most complex and intricate molecular machine in human biology. Researchers at the Centre for Genomic Regulation (CRG) in Barcelona have created the first…

A paper-aluminum combo for strong, sustainable packaging

Takeout containers get your favorite noodles from the restaurant to your dining table (or couch) without incident, but they are nearly impossible to recycle if they are made from foil-lined…